Intellia Therapeutics (NTLA) awarded an inducement grant to five new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units for 18,200 shares of Intellia’s common stock, with one-third of such RSUs vesting on August 1, 2026, 2027 and 2028. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates. All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN
- Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM
- Insider Sales Shake Up Southern Co, Constellation, Intellia, US Bancorp, and Kohl’s
- Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B
- Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?